Le Lézard
Classified in: Health
Subjects: MAV, DIS, DEI

Press conference - The scandal repeats itself and it's worse than ever: Mammograms are still denied to women with disabilities


Press conference
Intercontinental Hotel
360 St-Antoine Street West, Sherwood room
Montréal (Québec)
H2Y 3X4 
May 4, 2022 10.00 am

MONTREAL, May 3, 2022 /CNW Telbec/ - RAPLIQ invites you to a press conference at the above-mentioned address.

For a third time, we have conducted a study on the accessibility of designated screening centers (DSC).

Results are worse than ever !

In 2017, to follow up on the file, we redid the exercise by calling the 97 clinics registered on the site of the designated screening centers (DSC) of the Quebec breast cancer screening program (QBSCP).

We were bitterly disappointed to find that not only were access to mammography examinations still being refused to women in wheelchairs, but that this refusal was also falsely justified. Falsehoods such as: "the devices (mammographs) do not lower"; "you absolutely must transfer to a small stool", etc.

We are still getting humiliating remarks such as: "You really can't stand up at all at all? - "You must be able to stand" - "No, in your case, it's the hospital."

Documents will be included in the press kits to support our statement.

About RAPLIQ:

RAPLIQ is a pan-Quebec organization that supports and accompanies people with disabilities who are victims of discrimination to defend and claim their rights and to promote them by aiming to eradicate this discrimination too often made against them.

SOURCE RAPLIQ (Regroupement des activistes pour l'inclusion au Québec)


These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...



News published on and distributed by: